Citigroup
BIO icon

Citigroup’s Bio-Rad Laboratories Class A BIO Stock Holding History

Citigroup’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,600
Closed -$222K – 7457
2015
Q4 		$222K Buy
+1,600
New +$222K ﹤0.01% 4651

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citigroup's BIO Position: Q2 2026 in Review

Citigroup reduced its Bio-Rad Laboratories Class A (BIO) stake by 1.2% in Q2 2026, selling an estimated $17.3K and leaving 5,056 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #3155.

Citigroup first reported a position in BIO in Q2 2013 and has held it in 53 quarters since. The position peaked at $14.9M in Q2 2025. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Citigroup held 5,056 shares of Bio-Rad Laboratories Class A worth $1.48M as of Q2 2026.
  • Citigroup sold 61 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $17.3K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3155 holding.
  • Citigroup first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 53 quarters since.
  • Citigroup's Bio-Rad Laboratories Class A position peaked at $14.9M in Q2 2025.
  • 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.